Pharsight

Averitas patents expiration

1. Qutenza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869827 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(23 days ago)

US8263059 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(23 days ago)

US8889113 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(23 days ago)

US10463598 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(23 days ago)

US10034841 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
Sep, 2025

(1 year, 11 months from now)

US9226903 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer
Dec, 2028

(5 years from now)

US8821920 AVERITAS Therapeutic patch for transdermal delivery of capsaicin
Mar, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jul 17, 2023

Drugs and Companies using CAPSAICIN ingredient

Market Authorisation Date: 16 November, 2009

Treatment: Method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area

Dosage: PATCH;TOPICAL

More Information on Dosage

QUTENZA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic